Cover image for Vol. 35 Issue 6

Edited By: Jan A. Nolta

Impact Factor: 5.902

ISI Journal Citation Reports © Ranking: 2015: 3/21 (CELL & TISSUE ENGINEERING); 8/70 (Hematology); 14/161 (Biotechnology & Applied Microbiology); 24/213 (Oncology); 34/187 (Cell Biology)

Online ISSN: 1549-4918

Associated Title(s): STEM CELLS Translational Medicine

About AlphaMed

A Brief History of AlphaMed Press

AlphaMed Press was founded in Ohio in 1983 and relocated to Durham, North Carolina, 22 years later. AlphaMed Press publishes three internationally renowned peer-reviewed journals: THE ONCOLOGIST®, a cancer medicine journal for those entrusted with cancer patient care; STEM CELLS Translational Medicine®, dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology; and STEM CELLS®. STEM CELLS is the oldest journal in the fast-paced area of stem cells and regenerative medicine. Not only is it the first journal to be devoted to this promising research, it remains in the top tier of peer-reviewed monthly journals for this discipline.

Established in 1981 by scientists in the service of science, the Journal’s founding editors were Donald Metcalf, Fumimaro Takaku, and the late Laszlo Lajtha, with Martin Murphy, Jr. serving as Editor-in-Chief. This was at the dawn of the stem cell field in which hematopoietic stem cells were confined to the laboratory bench, far from clinical deployment. STEM CELLS was published by Karger in Switzerland from 1981 to 1983. AlphaMed Press began publishing the Journal in 1983, assuming the temporary title The International Journal of Cell Cloning until 1994, when the Journal reclaimed its founding name, STEM CELLS, which was then trademarked on the Primary Register.

During the Journal’s first decade, hematopoietic stem cells were being purified and transplanted, manipulated and genetically engineered — in short, a new horizon of opportunities in clinical medicine had emerged. Accordingly, the Editorial Board addressed clinical applications of stem cells, their separation, gene transplantation, and other topics within this broad range.

In 2000, Curt Civin was appointed the Journal’s second Editor-in-Chief, a position he continued for eight years of unprecedented growth in the Journal's impact factor, number of articles published, and number of manuscripts submitted. During Civin’s tenure as Editor-in-Chief, STEM CELLS was also led by three Senior Editors: Alan Gewirtz, Robert Hawley, and Margaret Goodell. With the benefit of a cumulative 26 years of expertise in the field, they instilled the rigorous review process of original articles and concise reviews describing basic laboratory investigations of stem cells and the translation to patient clinical trials. The Journal also provided a forum for young investigators to present provocative proposals for new research directions.

In 2007, Donald Phinney and Miodrag Stojković succeeded Civin as the Journal’s Co-Editors. They both admirably served as the Journal’s Associate Editors prior to continuing the Journal’s practice providing articles of the highest quality. As Co-Editors, they worked closely with a team of four Associate Editors: Jan Nolta, Majlinda Lako, Margaret Baron, and Mark Pittenger to maintain the standards of excellence in research that the Journal has achieved over more than quarter of a century.

In 2009, AlphaMed Press announced the promotion of Stojković to Editor. Stojković worked with associate editors Nolta, Lako, and Pittenger to guide the journal from 2009 to 2011.

In January 2012, STEM CELLS celebrated its 30th anniversary with the promotion of Jan Nolta as its Editor. Nolta is the Director of the Stem Cell program at UC Davis which examines the recruitment of human adult and ESC to areas of tissue damage in immune deficient mice, with the aim of developing improved therapies for treating disease. She was a member of the University of Southern California team that succeeded in the first gene therapy trial to treat newborns for ADA deficiency; this shaped her career in translational medicine. Since then, she has specialized in translational, or bench-to-bedside science, and has been involved in 18 clinical trials of gene and cell therapy. In 2014, Nolta was promoted to Editor-in-Chief of the Journal.

Two additional Associate Editors were recently appointed: Noel Buckley in 2012 and Toru Kondo in 2014. Long-time Associate Editor Mark Pittenger stepped down at the end of 2013, after serving for six years and playing a fundamental role in helping STEM CELLS remain at the top of the field.

AlphaMed Press also publishes the STEM CELLS Portal online. Launched in June 2007, the Portal was redesigned at the end of 2013 to become the hub for the STEM CELLS and STEM CELLS Translational Medicine sister journals and a resource for clinical investigators and research scientists. The Portal provides an interactive, up-to-the-minute platform covering the latest research from bench science and developments in clinical applications. The Portal is led by Editor Lyle Armstrong and his editorial team of Stuart Atkinson and Carla Mellough.

Today, STEM CELLS continues to cover all aspects of stem cells and regenerative medicine: Embryonic Stem Cells/Induced Pluripotent Stem (iPS) Cells; Tissue-Specific Stem Cells; Stem Cell Technology: Epigenetics, Genomics, Proteomics, and Metabonomics; Cancer Stem Cells; Translational and Clinical Research; and Regenerative Medicine.